High Risk Coronary Artery Stenting and Angioplasty

Heart disease is one of the most common causes of death in the United States. Every year more than 250, 000 die of heart attack. The most common problem is coronary artery disease which is buildup of fat and cholesterol materials on the wall of the arteries called atheroscleroticplaque. This results in blockage and reduced blood flow to the heart muscles which can cause angina and heart attack. In the 60’s and 70’s open heart bypass(CABG) surgery was the only option available to treat them. In 1970’s balloon angioplasty was introduced to open up blockages but there were major problems of restenosis with balloon angioplasty alone. To deal with this issue in early 1990’s STENTS were found to be effective. However, they too had restenosis issue as the major handicap for treatment of coronary artery blockages.Finally, DES – Drug Eluting Stents were introduced which have almost completely resolved the restenosis issue. DES is now the standard for treating coronary artery blockages. Dr Shahab specializes in stenting of coronary arteries and has performed several thousands of these procedures for the last 20 years. Hetreats high risk cases including patients who have multiple blockages in all three arteries and who are not candidate for open heart bypass surgery or who do not want to go for surgery. He has presented many research papers at national and international meetings and have written several papers on this subject which are published in major US medical journals.
Shawl FA, Domanski MJ, Kaul UP,Rigali G and Shahab ST:Percutaneous Transluminal Myocardial Revascularization: Procedural Results and Clinical Outcome. Am J Cardiol; Feb 1999; 83: 498-501.

Shahab ST and Booth DC.  Long Term Follow-up of Acute Myocardial Infarction treated with Reperfusion Therapy – the KAMIT follow-up Study.Presented at AFCR/ASCI Annual Meet May 1994. 
‍
Principal Investigator: Safety and Efficacy of Jomed Jostent Coronary Stent Graft in the treatment of free coronary perforations during coronary interventions.  – Virginia Hospital Center. 
‍
Co-Investigator: Fiber-Optic (SAFER) wire use in opening total coronary occlusions. – Inova Fairfax Hospital.
‍
Principal Investigator: KAMIT: Kentucky Acute Myocardial Infarction Follow-up Study; University of Kentucky. 
‍
Co-Investigator: BRAVO – Blockade of the GP IIb/IIIa Receptor to avoid Vascular Occlusion. Lotrafiban Protocol # SB 214857/030; University of Louisville. 
‍
Co-Investigator: Efficacy of rhuMAB CD 18 in Acute Myocardial Infarction, a phase II trial. Protocol SO826g; University of Louisville. 
‍
Co-Investigator: OVERTURE – Omapatrilat versus Enalapril Randomized Trial of utility in Reducing Events. USIND # 48305.BMS CV 137-068 
Co-Investigator: AMISTAD II – A Randomized Double Blind Placebo Controlled Multi-Center Trial to Evaluate the Efficacy and Safety of Adenosine as an Adjunct to Reperfusion Therapy in the treatment of Acute MI; University of Louisville. 
Co-Investigator TIMI 10-B: A Multi-Center Trial comparing a new thrombolytic agent – TNKtpa vs. TPA; University of Louisville. 
Co-Investigator: TIMI 11 B: A Multi-Center Trial comparing a Low-Molecular Weight Heparin (Enoxaprin) to Unfractionated Heparin in patients with Unstable Angina; University of Louisville. 
Co-Investigator: AMISTAD: Adenosine added to cardioplegia has a myocardial protective effect during CABG – A Multi-Center Trial; University of Louisville. Co-Investigator: SMART: A new GFX/GFX XL – Acute or Threatened Closure Registry; ICRI, Washington Adventist Hospital.
Co-Investigator: A Phase II Trial of the Safety and Efficacy of Percutaneous Transluminal Myocardial Revascularization (PTMR) in patients with Refractory Angina. 
Co-Investigator: EXTRA: Evaluation of the Bard-XT Stent for Restenosis innative arteries. IDE # G970063; Washington Adventist Hospital. 
‍
Co-Investigator: EXCITE: Efficacy and Safety of Xemilofiban HCl in patients undergoing coronary angioplasty. IND # 46247; Washington Adventist Hospital.